Lucia Farina

Medicine & Life Sciences

1. B-Cell Chronic Lymphocytic Leukemia 100%
2. Stem Cell Transplantation 78%
3. Allogeneic Cells 70%
4. Rituximab 68%
5. Lymphoma 64%
6. PCI 32765 45%
7. Survival 43%
8. Non-Hodgkin's Lymphoma 38%
9. Bendamustine Hydrochloride 36%
10. Hepacivirus 35%
11. Lymphoma, Large B-Cell, Diffuse 34%
12. Progression-Free Survival 33%
13. Hodgkin Disease 33%
14. plerixafor octahydrochloride 30%
15. Mortality 29%
16. Homologous Transplantation 28%
17. Transplants 25%
18. B-Cell Lymphoma 25%
19. Antiviral Agents 25%
20. Hematopoietic Stem Cell Transplantation 24%
21. Recurrence 24%
22. Tissue Donors 24%
23. Chemokine CCL17 24%
24. Multiple Myeloma 20%
25. Therapeutics 20%
26. Bone Marrow 18%
27. Residual Neoplasm 17%
28. Autologous Transplantation 17%
29. Hematologic Diseases 16%
30. Alemtuzumab 15%
31. idelalisib 15%
32. Multicenter Studies 15%
33. Hematopoietic Stem Cell Mobilization 15%
34. Hematologic Neoplasms 15%
35. Chronic Hepatitis C 15%
36. Salvage Therapy 14%
37. Drug Therapy 14%
38. Cyclophosphamide 14%
39. Granulocyte Colony-Stimulating Factor 14%
40. Incidence 14%
41. Follicular Lymphoma 13%
42. Peripheral T-Cell Lymphoma 13%
43. Graft vs Host Disease 13%
44. Lenalidomide 12%
45. Registries 12%
46. Coronavirus 12%
47. T-Lymphocytes 11%
48. Sorafenib 11%
49. Virus Diseases 11%
50. Staphylococcal Protein A 11%